Roche Holding AG Price & Performance (RHHBY)

Roche reported a 6% increase in group sales for Q1 2025, reaching CHF 15.4 billion, with pharmaceutical sales up 8%. Growth was fueled by high demand for new medicines, offsetting flat diagnostics performance due to pricing reforms in China. The company reaffirmed its full-year guidance and plans further dividend increases.12

Analyst consensus remains positive for Roche Holding AG, with several firms reiterating Buy ratings and forecasting double-digit upside potential. While recent profits dipped, Roche's robust pipeline and planned $50 billion U.S. investment support long-term growth prospects, even as the company faces currency headwinds and global pricing challenges.34

Roche shareholders endured a 21% loss over three years, but recent returns have improved, with a 20% total shareholder return in the past year. Despite ongoing market volatility and earnings challenges, some observers suggest a potential turning point as the company’s fundamentals and dividend policy remain strong.56